An Oral, Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib (BMS-986165), Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis

Main Article Content

Bruce Strober
Alice Gottlieb
Diamant Thaçi
Luis Puig
Matthew Colombo
Sudeep Kundu
Renata Kisa
Subhashis Banerjee

Keywords

Psoriasis, Tyrosine Kinase 2 Inhibitor, TYK2 Inhibitor, Oral, Efficacy

Abstract

Abstract not available.

References

1. Weigle N, McBane S. Am Fam Physician. 2013;87(9):626-633.

2. Puig L et al. Acta Derm Venereol. 2019;99(11):971-977.

3. Papp K et al. N Engl J Med. 2018;379(14):1313-1321.